Pfizer Inc (PFE) KPIs and segments
Close on Nov 17, 2026Market cap $162.27BP/E 37.5Yield 6.04%
KPI & bộ phận
Chỉ số vận hành và bộ phận làm nên hoạt động của Pfizer · năm tài chính kết thúc December 31 (international subsidiaries generally report interim quarters on a one-month lag; FY2025 ended December 31, 2025; Q2 2026 ended June 28, 2026)
Nhìn nhanh KPI của Pfizer: 81 chỉ số vận hành, trong đó có Total R&D Pipeline Programs, Patients Treated Worldwide và U.S. Portfolio Average Net Price Change YoY, lấy từ 156 tài liệu nguồn, cùng doanh thu theo bộ phận, sản phẩm và khu vực từ hồ sơ SEC. Mỗi số đều dẫn tới tài liệu gốc. Tất cả chỉ số hiện cả bảng; Cốt lõi chỉ giữ bộ phận và KPI nổi bật. Bảng bộ phận còn có cách xem lũy kế 12 tháng.
Biểu đồ đang trống. Tick vào ô cạnh bất kỳ chỉ số nào ở bảng dưới để vẽ — tick nhiều chỉ số để so sánh trên cùng một biểu đồ.
Bộ phận, KPI nổi bật và mọi chỉ số vận hành từ hồ sơ, thông cáo kết quả và bản trình bày.
| Thêm vào biểu đồ | Chỉ số | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Product($M) | 11,863 | 11,715 | 14,495 | 13,920 | 11,954 | 11,294 | 15,085 | 15,417 | 10,871 | 12,443 | 12,339 | 11,587 | |
Royalty($M) | 474 | 396 | 480 | 436 | 426 | 308 | 431 | 384 | 345 | 263 | 321 | 260 | |
Pfizer CentreOne($M) | 373 | 289 | 409 | 344 | 348 | 273 | 326 | 285 | 278 | 258 | |||
Pfizer Ignite($M) | 4 | 0 | 20 | 17 | 26 | 25 | 15 | 17 | |||||
Kỳ báo cáo trước đây (báo cáo lần cuối 2024)1 | |||||||||||||
United States($M) | 8,857 | 8,731 | 9,119 | 10,691 | 8,894 | 8,374 | 9,221 | 12,064 | 7,892 | 9,514 | 4,912 | 8,064 | |
International Developed Markets($M) | 3,743 | 3,426 | 5,921 | 3,696 | 3,393 | 3,178 | 6,283 | 3,412 | 3,164 | 3,198 | 7,816 | 3,335 | |
International Emerging Markets($M) | 2,434 | 2,293 | 2,517 | 2,267 | 2,366 | 2,163 | 2,259 | 2,226 | 2,227 | 2,167 | 1,842 | 2,092 | |
Kỳ báo cáo trước đây (báo cáo lần cuối 2023)3 | |||||||||||||
Kỳ báo cáo trước đây (báo cáo lần cuối 2026)4 | |||||||||||||
Kỳ báo cáo trước đây (báo cáo lần cuối 2026)1 | |||||||||||||
Remaining performance obligations (RPO)($M) | 9,000 | ||||||||||||
Total R&D Pipeline Programs (Phase 1 through Registration)12 | 95 | 96 | 102 | 101 | 108 | ||||||||
Registration programs | 2 | 5 | 2 | 4 | 4 | ||||||||
Phase 3 clinical programs | 25 | 25 | 30 | 30 | 30 | ||||||||
Phase 2 clinical programs | 37 | 35 | 38 | 37 | 46 | ||||||||
Phase 1 clinical programs | 31 | 31 | 32 | 30 | 28 | ||||||||
New Molecular Entities (NMEs) in pipeline | 56 | 57 | 61 | 59 | |||||||||
Additional Indications in pipeline | 39 | 39 | 41 | 42 | |||||||||
Programs advanced or new since prior quarter | 12 | 10 | 15 | 11 | |||||||||
Programs discontinued since prior quarter | 7 | 7 | 9 | 11 | |||||||||
Oncology — Total programs in pipeline4 | 56 | 51 | 56 | 57 | |||||||||
Inflammation & Immunology — Total programs in pipeline4 | 18 | 21 | 22 | 24 | |||||||||
Internal Medicine — Total programs in pipeline4 | 11 | 14 | 14 | 10 | |||||||||
Vaccines — Total programs in pipeline4 | 10 | 10 | 10 | 10 | |||||||||
Consolidated Operational Revenue Growth Excluding Comirnaty & Paxlovid YoY (%)(%)1 | 5.0% | 7.0% | 9.0% | 4.0% | 11.0% | 14.0% | 14.0% | 11.0% | 8.0% | 10.0% | |||
Foreign Exchange (FX) Impact on Consolidated Revenues YoY ($M)($M) | 217 | 431 | 278 | 203 | 22 | -256 | 62 | -133 | -170 | -107 | |||
Full-Year Revenue Guidance — Lower end ($M)($M)8 | 60,500 | 59,500 | 61,000 | 61,000 | 61,000 | 61,000 | 59,800 | 61,000 | 59,500 | 58,500 | 58,000 | 58,000 | |
Deferred Revenue / Contract Liabilities — Government COVID-19 supply agreements ($M)($M)4 | 1,400 | 1,500 | 1,500 | 1,800 | 1,900 | 1,900 | 2,200 | 3,500 | 4,300 | 4,100 | 5,100 | ||
Government COVID-19 contract liabilities — Current ($M)($M) | 521 | 646 | 689 | 790 | 1,000 | 932 | 1,400 | 2,000 | 2,500 | 2,400 | 2,600 | ||
Government COVID-19 contract liabilities — Noncurrent ($M)($M) | 855 | 816 | 826 | 1,000 | 906 | 977 | 785 | 1,500 | 1,800 | 1,600 | 2,500 | ||
Remaining Performance Obligations (RPO) — Comirnaty multi-year contracts ($M)($M) | 2,000 | 2,100 | 2,100 | 3,000 | 4,000 | 3,000 | 4,000 | 6,000 | 6,000 | 6,000 | 6,000 | ||
Remaining Performance Obligations (RPO) — Paxlovid multi-year contracts ($M)($M) | 965 | 948 | 1,000 | 1,000 | 1,000 | 1,000 | 1,000 | 1,000 | 2,000 | 2,000 | 3,400 | ||
Eliquis (apixaban — BMS alliance & direct sales) — Worldwide revenues ($M)($M)4 | 2,425 | 2,166 | 2,020 | 2,015 | 2,003 | 1,923 | 1,832 | 1,617 | 1,877 | 2,040 | 1,612 | 1,498 | |
Eliquis (apixaban — BMS alliance & direct sales) — U.S. revenues ($M)($M)1 | 1,651 | 1,435 | 1,235 | 1,292 | 1,322 | 1,299 | 1,126 | 1,002 | 1,262 | 1,413 | 931 | 883 | |
Eliquis (apixaban — BMS alliance & direct sales) — International revenues ($M)($M)2 | 773 | 731 | 785 | 723 | 681 | 624 | 705 | 616 | 615 | 626 | 681 | 615 | |
Eliquis (apixaban — BMS alliance & direct sales) — Worldwide reported YoY (%)(%) | 21.0% | 13.0% | 10.0% | 25.0% | 7.0% | -6.0% | 14.0% | 8.0% | 7.0% | 9.0% | 9.0% | 2.0% | |
Eliquis (apixaban — BMS alliance & direct sales) — Worldwide operational (constant-currency) YoY (%)(%) | 19.0% | 8.0% | 8.0% | 22.0% | 6.0% | -4.0% | 13.0% | 9.0% | 8.0% | 10.0% | 9.0% | 3.0% | |
Prevnar Family (Prevnar 20 / Apexxnar & Prevnar 13 pneumococcal vaccines) — Worldwide revenues ($M)($M)4 | 1,337 | 1,690 | 1,708 | 1,742 | 1,383 | 1,660 | 1,558 | 1,803 | 1,359 | 1,691 | 1,624 | 1,843 | |
Prevnar Family (Prevnar 20 / Apexxnar & Prevnar 13 pneumococcal vaccines) — U.S. revenues ($M)($M)1 | 748 | 1,053 | 966 | 1,155 | 860 | 1,170 | 944 | 1,308 | 832 | 1,149 | 1,012 | 1,299 | |
Prevnar Family (Prevnar 20 / Apexxnar & Prevnar 13 pneumococcal vaccines) — International revenues ($M)($M)2 | 589 | 637 | 742 | 587 | 523 | 491 | 614 | 495 | 527 | 542 | 612 | 544 | |
Prevnar Family (Prevnar 20 / Apexxnar & Prevnar 13 pneumococcal vaccines) — Worldwide reported YoY (%)(%) | -3.0% | 2.0% | 10.0% | -3.0% | 2.0% | -2.0% | -4.0% | -2.0% | -5.0% | 6.0% | -8.0% | 15.0% | |
Prevnar Family (Prevnar 20 / Apexxnar & Prevnar 13 pneumococcal vaccines) — Worldwide operational (constant-currency) YoY (%)(%) | -4.0% | -1.0% | 8.0% | -4.0% | 2.0% | -1.0% | -4.0% | -2.0% | -4.0% | 7.0% | -7.0% | 15.0% | |
Comirnaty (COVID-19 mRNA vaccine — BioNTech collaboration) — Worldwide revenues ($M)($M)4 | 261 | 232 | 2,271 | 1,151 | 381 | 565 | 3,383 | 1,422 | 195 | 354 | 5,361 | 1,306 | |
Paxlovid (nirmatrelvir/ritonavir oral COVID-19 treatment) — Worldwide revenues ($M)($M)4 | 21 | 186 | 218 | 1,225 | 427 | 491 | 727 | 2,703 | 251 | 2,035 | -3,135 | 202 | |
Nurtec ODT / Vydura (rimegepant — migraine, acquired via Biohaven) — Worldwide revenues ($M)($M)4 | 421 | 353 | 405 | 412 | 359 | 248 | 392 | 337 | 356 | 178 | 282 | 233 | |
Abrysvo (bivalent RSV vaccine — maternal & older adults) — Worldwide revenues ($M)($M)2 | 208 | 180 | 481 | 279 | 143 | 131 | 198 | 356 | 56 | 145 | 515 | 375 | |
FSME-IMMUN / TicoVac (tick-borne encephalitis vaccine) — Worldwide revenues ($M)($M)3 | 132 | 81 | 47 | 100 | 109 | 63 | 34 | 81 | 100 | 30 | 91 | ||
All Other Primary Care — Worldwide revenues ($M)($M)3 | 699 | 654 | 789 | 721 | 731 | 609 | 787 | 742 | 759 | 770 | 571 | 670 | |
Primary Care Portfolio Total [legacy pre-Q1 2026 realignment, through Q4 2025] ($M)($M)4 | 7,938 | 7,646 | 5,540 | 5,696 | 8,911 | 9,060 | 4,952 | 7,211 | 7,044 | 6,310 | |||
Ibrance (palbociclib — HR+/HER2- metastatic breast cancer) — Worldwide revenues ($M)($M)3 | 1,058 | 1,008 | 1,040 | 1,057 | 1,049 | 977 | 1,095 | 1,087 | 1,130 | 1,054 | 1,118 | 1,244 | |
Ibrance (palbociclib — HR+/HER2- metastatic breast cancer) — U.S. revenues ($M)($M)1 | 707 | 632 | 686 | 670 | 696 | 659 | 713 | 717 | 741 | 679 | 712 | 838 | |
Ibrance (palbociclib — HR+/HER2- metastatic breast cancer) — International revenues ($M)($M)2 | 351 | 376 | 354 | 387 | 353 | 318 | 382 | 371 | 390 | 375 | 405 | 406 | |
Ibrance (palbociclib — HR+/HER2- metastatic breast cancer) — Worldwide reported YoY (%)(%) | 1.0% | 3.0% | -5.0% | -3.0% | -7.0% | -7.0% | -2.0% | -13.0% | -9.0% | -8.0% | -13.0% | -3.0% | |
Xtandi (enzalutamide — alliance & royalty revenue with Astellas) — Worldwide revenues ($M)($M)3 | 534 | 444 | 592 | 578 | 566 | 458 | 565 | 561 | 495 | 418 | 457 | 440 | |
Xtandi (enzalutamide — alliance & royalty revenue with Astellas) — U.S. revenues ($M)($M)1 | 534 | 444 | 592 | 578 | 566 | 458 | 565 | 561 | 495 | 418 | 457 | 440 | |
Xtandi (enzalutamide — alliance & royalty revenue with Astellas) — Worldwide reported YoY (%)(%) | -6.0% | -3.0% | 5.0% | 3.0% | 14.0% | 9.0% | 24.0% | 28.0% | 17.0% | 23.0% | -2.0% | -2.0% | |
Xtandi (enzalutamide — alliance & royalty revenue with Astellas) — Worldwide operational (constant-currency) YoY (%)(%) | -6.0% | -3.0% | 5.0% | 3.0% | 14.0% | 9.0% | 24.0% | 28.0% | 17.0% | 23.0% | -2.0% | -2.0% | |
Padcev (enfortumab vedotin ADC — urothelial cancer, via Seagen) — Worldwide revenues ($M)($M)4 | 667 | 591 | 508 | 464 | 542 | 426 | 444 | 409 | 394 | 341 | 53 | 0 | |
Padcev (enfortumab vedotin ADC — urothelial cancer, via Seagen) — U.S. revenues ($M)($M)1 | 648 | 585 | 500 | 449 | 534 | 419 | 433 | 407 | 387 | 334 | 53 | ||
Padcev (enfortumab vedotin ADC — urothelial cancer, via Seagen) — International revenues ($M)($M) | 19 | 7 | 8 | 16 | 7 | 7 | 11 | 2 | 7 | 7 | |||
Padcev (enfortumab vedotin ADC — urothelial cancer, via Seagen) — Worldwide reported YoY (%)(%) | 23.0% | 39.0% | 15.0% | 13.0% | 38.0% | 25.0% | |||||||
Padcev (enfortumab vedotin ADC — urothelial cancer, via Seagen) — Worldwide operational (constant-currency) YoY (%)(%) | 23.0% | 39.0% | 15.0% | 13.0% | 38.0% | 25.0% | |||||||
Lorbrena / Lorviqua (lorlatinib — ALK+ NSCLC) — Worldwide revenues ($M)($M)4 | 354 | 305 | 282 | 268 | 251 | 222 | 192 | 206 | 169 | 164 | 146 | 159 | |
Adcetris (brentuximab vedotin ADC — lymphoma, via Seagen) — Worldwide revenues ($M)($M)4 | 196 | 190 | 220 | 215 | 255 | 218 | 285 | 268 | 279 | 257 | 56 | 0 | |
Inlyta (axitinib — renal cell carcinoma) — Worldwide revenues ($M)($M)4 | 218 | 214 | 235 | 226 | 243 | 219 | 242 | 247 | 252 | 237 | 263 | 252 | |
Braftovi + Mektovi (encorafenib / binimetinib — BRAF+ melanoma/CRC/NSCLC) — Worldwide revenues ($M)($M)4 | 223 | 174 | 197 | 202 | 182 | 136 | 170 | 173 | 148 | 116 | 131 | 131 | |
Bosulif (bosutinib — CML) — Worldwide revenues ($M)($M)4 | 113 | 129 | 161 | 150 | 149 | 151 | 171 | 161 | 167 | 145 | 182 | 160 | |
Tukysa (tucatinib — HER2+ breast/colorectal cancer, via Seagen) — Worldwide revenues ($M)($M)4 | 138 | 122 | 119 | 110 | 132 | 102 | 129 | 124 | 121 | 106 | 18 | 0 | |
Orgovyx (relugolix — prostate cancer, Sumitomo collaboration) — Worldwide revenues ($M)($M)1 | 146 | 109 | 136 | 112 | 97 | 76 | 64 | 57 | |||||
Elrexfio (elranatamab — BCMA bispecific for multiple myeloma) — Worldwide revenues ($M)($M)4 | 89 | 80 | 74 | 85 | 85 | 60 | 57 | 40 | 22 | 13 | 6 | ||
Talzenna (talazoparib — PARP inhibitor) — Worldwide revenues ($M)($M)4 | 57 | 50 | 49 | 47 | 46 | 40 | 27 | 36 | 32 | 23 | 22 | 20 | |
Tivdak (tisotumab vedotin ADC — cervical cancer, via Seagen) — Worldwide revenues ($M)($M)3 | 34 | 33 | 32 | 37 | 46 | 33 | 36 | 34 | 33 | 28 | 4 | 0 | |
All Other Oncology — Worldwide revenues ($M)($M)3 | 338 | 376 | 303 | 272 | 394 | 377 | 286 | 268 | 347 | 301 | 411 | 399 | |
Oncology Portfolio Total [legacy incl. Oncology Biosimilars, through Q4 2025] ($M)($M)4 | 4,435 | 4,253 | 4,387 | 3,758 | 4,064 | 4,043 | 3,956 | 3,549 | 3,189 | 3,115 | |||
Vyndaqel Family (Vyndaqel / Vyndamax / Vynmac — ATTR-CM) — Worldwide revenues ($M)($M)4 | 1,762 | 1,602 | 1,688 | 1,591 | 1,615 | 1,486 | 1,545 | 1,447 | 1,323 | 1,137 | 961 | 892 | |
Vyndaqel Family (Vyndaqel / Vyndamax / Vynmac — ATTR-CM) — U.S. revenues ($M)($M)1 | 1,064 | 911 | 910 | 948 | 990 | 986 | 975 | 960 | 861 | 751 | 534 | 511 | |
Vyndaqel Family (Vyndaqel / Vyndamax / Vynmac — ATTR-CM) — International revenues ($M)($M)2 | 698 | 691 | 778 | 643 | 626 | 499 | 570 | 486 | 462 | 386 | 427 | 381 | |
Vyndaqel Family (Vyndaqel / Vyndamax / Vynmac — ATTR-CM) — Worldwide reported YoY (%)(%) | 9.0% | 8.0% | 9.0% | 10.0% | 22.0% | 31.0% | 61.0% | 62.0% | 69.0% | 66.0% | 41.0% | 48.0% | |
Vyndaqel Family (Vyndaqel / Vyndamax / Vynmac — ATTR-CM) — Worldwide operational (constant-currency) YoY (%)(%) | 8.0% | 4.0% | 7.0% | 7.0% | 21.0% | 33.0% | 60.0% | 63.0% | 71.0% | 66.0% | 39.0% | 47.0% | |
Xeljanz (tofacitinib — rheumatoid arthritis / ulcerative colitis) — Worldwide revenues ($M)($M)4 | 251 | 180 | 324 | 313 | 322 | 128 | 349 | 321 | 303 | 194 | 493 | 503 | |
Oncology Biosimilars Portfolio (Ruxience, Zirabev, Trazimera, Nivestym, Nyvepria) — Worldwide revenues ($M)($M)4 | 359 | 409 | 369 | 315 | 353 | 264 | 209 | 285 | 279 | 264 | 322 | 310 | |
Sulperazon (cefoperazone/sulbactam — hospital anti-infective) — Worldwide revenues ($M)($M)1 | 116 | 199 | 169 | 154 | 166 | 164 | 170 | 156 | 144 | 167 | 138 | 122 | |
Octagam / Panzyga (immunoglobulin portfolio) — Worldwide revenues ($M)($M)3 | 138 | 122 | 120 | 113 | 96 | 88 | 109 | 221 | 104 | 81 | 53 | ||
Inflectra / Remsima (infliximab biosimilar) — Worldwide revenues ($M)($M)4 | 171 | 182 | 181 | 173 | 139 | 153 | 127 | 126 | 97 | 158 | 117 | 121 | |
Zavicefta (ceftazidime/avibactam — Gram-negative anti-infective) — Worldwide revenues ($M)($M)3 | 199 | 150 | 181 | 158 | 163 | 135 | 159 | 152 | 150 | 125 | 133 | 130 | |
Enbrel (etanercept — international outside U.S./Canada) — Worldwide revenues ($M)($M)3 | 142 | 138 | 180 | 154 | 154 | 140 | 183 | 169 | 179 | 159 | 203 | 208 | |
Genotropin (somatropin — growth hormone) — Worldwide revenues ($M)($M)4 | 94 | 93 | 117 | 128 | 106 | 95 | 112 | 119 | 119 | 120 | 160 | 158 | |
Zithromax (azithromycin) — Worldwide revenues ($M)($M)3 | 42 | 112 | 113 | 73 | 56 | 158 | 122 | 83 | 74 | 200 | 152 | 60 | |
Cibinqo (abrocitinib — atopic dermatitis) — Worldwide revenues ($M)($M)4 | 94 | 76 | 78 | 79 | 69 | 58 | 64 | 63 | 47 | 42 | 37 | 37 | |
All Other Specialty Care — Worldwide revenues ($M)($M)4 | 566 | 579 | 477 | 407 | 453 | 486 | 345 | 323 | 429 | 513 | 217 | 202 | |
Total Biopharma Alliance Revenues (cross-portfolio summary) — Worldwide revenues ($M)($M)4 | 2,697 | 2,339 | 2,582 | 2,298 | 2,273 | 2,113 | 2,248 | 1,900 | 2,067 | 2,172 | 1,910 | 1,645 | |
Total Biopharma Royalty Revenues (cross-portfolio summary) — Worldwide revenues ($M)($M)4 | 474 | 396 | 480 | 436 | 426 | 308 | 431 | 384 | 345 | 263 | 321 | 260 | |
Pfizer CentreOne (Contract Development & Manufacturing Organization — CDMO) — Worldwide revenues ($M)($M)4 | 373 | 289 | 409 | 344 | 348 | 273 | 325 | 285 | 278 | 258 | 364 | 293 | |
Specialty Care Portfolio Total [legacy pre-Q1 2026 realignment, through Q4 2025] ($M)($M)4 | 4,771 | 4,411 | 4,378 | 3,987 | 4,438 | 4,289 | 4,083 | 3,843 | 3,953 | 3,763 | |||
U.S. Commercial Division Revenues [legacy 2024–2025 structure] ($M)($M)2 | 9,031 | 10,599 | 8,793 | 8,285 | 9,114 | 11,964 | 7,828 | 9,426 | 11,070 | 5,864 | |||
Historical / Mature / Divested Brands [legacy disclosures] — Vyndaqel/Hospital/Upjohn history ($M)14 | |||||||||||||
Total Gross-to-Net (GTN) Rebate, Chargeback & Return Accruals ($M)($M)4 | 12,128 | 11,550 | 11,666 | 12,940 | 11,667 | 10,945 | 10,822 | 12,097 | 9,401 | 8,481 | 9,014 | 7,757 | |
Accrued rebates — Medicaid, Medicare & commercial contracting (Current liabilities) ($M)($M) | 9,293 | 8,846 | 7,909 | 9,157 | 8,692 | 8,119 | 7,195 | 8,252 | 6,726 | 5,880 | 5,546 | 5,083 | |
Allowance against trade accounts receivable — Chargebacks, discounts & returns ($M)($M) | 1,741 | 1,699 | 1,803 | 2,148 | 1,589 | 1,462 | 1,627 | 1,955 | 1,578 | 1,573 | 1,770 | 1,599 | |
Noncurrent accrued rebates & revenue deductions (Other noncurrent liabilities) ($M)($M) | 332 | 287 | 1,204 | 1,009 | 742 | 461 | 1,029 | 822 | 569 | 382 | 796 | 640 | |
Other current GTN accruals ($M)($M) | 763 | 718 | 750 | 625 | 644 | 904 | 972 | 1,068 | 529 | 646 | 902 | 436 | |
ViiV Healthcare Limited (HIV Joint Venture, 11.7% Pfizer Stake) — Standalone Net Revenues ($M)1 | |||||||||||||
ViiV Healthcare — Cash dividends paid to Pfizer ($M)($M) | 98 | 82 | 81 | 72 | 73 | 39 | 89 | 48 | 74 | 61 | 52 | 30 | |
Acquisition Contingent Consideration Liabilities — Current fair value ($M)($M)1 | 96 | 95 | 95 | 39 | 179 | ||||||||
Restructuring Reserve Liability — Total ending balance ($M)($M)16 | 1,682 | 1,588 | 1,910 | 1,836 | 1,986 | 2,399 | 2,120 | 2,132 | 2,399 | 1,638 | 1,988 | 585 | |
Restructuring reserve — Current liability ($M)($M) | 972 | 1,200 | 1,400 | 1,300 | 1,300 | 1,800 | 1,700 | 1,100 | 1,000 | 1,100 | 1,300 | 447 | |
Restructuring reserve — Noncurrent liability ($M)($M) | 710 | 431 | 466 | 532 | 685 | 562 | 437 | 1,100 | 1,400 | 519 | 663 | 137 | |
Restructuring reserve — Employee termination / severance costs ($M)($M) | 1,575 | 1,467 | 1,783 | 1,682 | 1,788 | 2,181 | 2,046 | 2,120 | 2,370 | 1,628 | 1,978 | 573 | |
Restructuring reserve — Exit & other restructuring activities ($M)($M) | 107 | 121 | 127 | 155 | 198 | 218 | 74 | 12 | 29 | 10 | 11 | 12 | |
Enterprise Cost Realignment Program (2023–2027) — Cumulative costs incurred to date ($M)($M) | 4,900 | 4,300 | 4,200 | 3,700 | 3,500 | 3,200 | 2,600 | 1,800 | 1,500 | 1,600 | 1,700 | ||
Cost Realignment Program — Cumulative costs attributable to Biopharma ($M)($M) | 3,800 | 3,300 | 3,200 | 2,900 | 2,700 | 2,700 | 2,100 | 1,400 | 1,200 | 1,300 | 674 | ||
Cost Realignment Program — Total expected program one-time costs ($M)($M) | 4,700 | 4,700 | 4,700 | 4,700 | 3,100 | 3,100 | |||||||
Manufacturing Optimization Program — Cumulative Phase 1 costs incurred to date ($M)($M) | 1,100 | 1,100 | 1,100 | 1,200 | 1,200 | 1,300 | 1,300 | ||||||
Manufacturing Optimization Program — Total expected Phase 1 costs ($M)($M) | 1,400 | 1,400 | 1,400 | 1,400 | 1,400 | 1,600 | 1,600 | 1,700 | 1,700 | ||||
Restructuring charges recognized in period — Total ($M)($M) | 419 | 49 | 308 | 237 | -74 | 621 | 656 | 217 | 1,104 | 10 | 1,803 | 71 | |
Restructuring charges — Employee termination costs ($M)($M) | 354 | 15 | 324 | 124 | -148 | 384 | 143 | 25 | 1,013 | -29 | 1,545 | 16 | |
Restructuring-related asset impairments ($M)($M) | 54 | 28 | 21 | 111 | 44 | 173 | 255 | 111 | 41 | 25 | 182 | 40 | |
Restructuring charges — Exit & other costs ($M)($M) | 11 | 6 | -37 | 2 | 30 | 64 | 258 | 82 | 49 | 14 | 75 | 15 | |
Restructuring reserve utilization / cash payments — Total ($M)($M) | 324 | 371 | 235 | 386 | 339 | 342 | 669 | 484 | 343 | 360 | 400 | 200 | |
Restructuring reserve utilization — Severance payments ($M)($M) | 247 | 330 | 223 | 230 | 245 | 249 | 216 | 275 | 272 | 320 | 140 | 144 | |
Acquisition integration & implementation costs ($M)($M) | 653 | 195 | 815 | 423 | 54 | 673 | 808 | 398 | 1,364 | 168 | 2,730 | 276 | |
Biopharma Operating Segment — Segment Pretax Income / Earnings ($M)($M)11 | 6,887 | 6,838 | 6,913 | 8,469 | 6,891 | 7,069 | 6,262 | 8,269 | 5,897 | 7,622 | 1,345 | -137 | |
Non-GAAP Adjusted Income Attributable to Pfizer Common Shareholders ($M)($M)1 | 4,440 | 4,290 | 3,786 | 4,949 | 4,434 | 5,237 | 3,592 | 6,050 | 3,400 | 4,674 | 593 | -968 | |
Non-GAAP Adjusted Diluted EPS ($/share)($) | 0.77 | 0.75 | 0.66 | 0.87 | 0.78 | 0.92 | 0.63 | 1.06 | 0.60 | 0.82 | 0.10 | -0.17 | |
Inventories — Work-in-process ($M)($M)4 | 5,160 | 5,713 | 5,634 | 6,038 | 6,514 | 5,553 | 6,101 | 7,267 | 7,072 | 6,273 | 5,688 | 6,515 | |
Inventories — Finished goods ($M)($M) | 3,887 | 4,031 | 4,113 | 4,485 | 4,126 | 4,162 | 3,775 | 3,280 | 3,220 | 3,491 | 3,495 | 2,892 | |
Inventories — Raw materials & supplies ($M)($M) | 898 | 923 | 907 | 945 | 1,029 | 1,137 | 976 | 1,174 | 1,156 | 1,128 | 1,007 | 797 | |
Noncurrent inventories (included in Other noncurrent assets) ($M)($M) | 2,419 | 2,462 | 2,370 | 2,142 | 2,360 | 2,793 | 2,663 | 2,765 | 2,918 | 3,361 | 4,568 | 1,416 | |
Supplier Finance Program — Confirmed obligations outstanding ($M)($M) | 545 | 518 | 574 | 566 | 501 | 546 | 688 | 628 | 593 | 658 | 791 | 781 | |
Finite-Lived Intangible Assets — Net carrying amount ($M)($M)7 | 29,273 | 30,918 | 31,510 | 33,513 | 34,028 | 34,622 | 35,848 | 37,340 | 38,594 | 39,899 | 40,116 | 27,830 | |
Property, Plant & Equipment — Gross carrying value ($M)2 | |||||||||||||
U.S. Defined Benefit Pension Plans — Projected benefit obligation (PBO) ($M)3 | |||||||||||||
U.S. Real Personal Consumption Expenditures — Pharmaceutical & Medical Products ($B SAAR)($M) | 3,790 | 3,700 | 3,667 | 3,615 | 3,530 | 3,465 | 3,418 | 3,358 | 3,288 | 3,244 | 3,159 | 3,079 | |
DB Segment — Biopharma Segment Revenues ($M)($M) | 14,661 | 14,161 | 17,143 | 16,310 | 14,305 | 13,441 | 17,413 | 17,392 | 12,991 | 14,604 | 14,186 | 13,188 | |
Consolidated Revenues ($M)($M)10 | 15,034 | 14,451 | 17,557 | 16,654 | 14,653 | 13,715 | 17,763 | 17,702 | 13,283 | 14,879 | 14,569 | 13,491 | |
Total Assets ($M)($M)9 | 201,131 | 207,618 | 208,160 | 208,731 | 206,095 | 208,028 | 213,396 | 219,476 | 216,193 | 221,095 | 226,501 | 215,021 | |
Operating Cash Flow ($M)($M)4 | 835 | 2,615 | 5,348 | 4,603 | -582 | 2,335 | 6,721 | 6,714 | -1,781 | 1,090 | 5,240 | 3,456 | |
152 chỉ số không có số liệu trong 12 quý gần nhất — .
In nghiêng là số StockData tự tính từ số đã báo cáo (rê chuột để xem công thức). Số có gạch chân chấm là số đọc từ câu chữ trong thông cáo kết quả và bản trình bày; rê chuột để xem đúng câu đó. Tick vào một dòng để thêm vào biểu đồ phía trên (tối đa 8 đường).
Phương pháp và các chỉ số bị loại
- Các dòng ở Cốt lõi lấy từ thuyết minh bộ phận và phân tách doanh thu trong hồ sơ 10-K và 10-Q (XBRL), có liên kết tới từng hồ sơ. Số quý 4 bằng cả năm tài chính trừ chín tháng đầu (hiện bằng chữ in nghiêng).
- Fiscal calendar & accounting basis: Pfizer Inc. operates on a calendar fiscal year ending December 31 in the U.S. (international operations are generally consolidated on a December–November fiscal year, with Q1–Q3 interim periods ending on the Sunday nearest March 31, June 30, and September 30; Q2 2026 ended June 28, 2026). Under US GAAP, Pfizer is exempt from parent-company-only Schedule I disclosures (restricted net assets of subsidiaries < 25% of consolidated net assets), so parent vs. subsidiary subtraction is not applicable.
- Q1 2026 Biopharma portfolio realignment: Beginning Q1 2026, Pfizer reorganized Biopharma revenues from three categories (Primary Care, Specialty Care, Oncology) into four categories by carving out Global Hospital & Biosimilars (sterile injectables, anti-infectives, and Oncology/Specialty biosimilars) without restating Q4 2025. Per RULES.md Step 5, pre-2026 category totals are preserved as explicitly labeled legacy series through Q4 2025, while individual medicine/vaccine series remain continuous across all periods.
- Core operational & commercial KPIs (Groups 1–9) cover: (1) R&D Pipeline snapshot (95 clinical programs at Q2 2026: 5 Registration, 27 Phase 3, 27 Phase 2, 36 Phase 1; 54 NMEs + 41 additional indications across Oncology, Inflammation & Immunology, Internal Medicine, and Vaccines), global patient reach (449M total / 335M ex-COVID patients treated in FY25), U.S. portfolio average net price change (-2% total / -5% ex-COVID in FY25), consolidated ex-COVID operational revenue growth (+5% in Q2 2026), full-year guidance ranges ($60.5B–$62.5B revenue and $2.80–$3.00 Adjusted Diluted EPS as of Q2 2026), and contracted Comirnaty/Paxlovid RPO & government COVID-19 contract liabilities ($2,756M at Q2 2026); (2–4) Worldwide, U.S., and International revenues plus reported & operational YoY % for 30+ active medicines/vaccines (led by Eliquis $2,099M, Prevnar family $1,422M, Vyndaqel family $1,796M, Ibrance $1,024M, Padcev $543M, Xtandi $594M, Nurtec ODT $407M in Q2 2026), Alliance/Royalty revenues, Pfizer CentreOne CDMO, and 20 historical LOE/Upjohn franchises; (5) Gross-to-Net rebate & chargeback balance-sheet reserves ($11,334M at Q2 2026 / $11,666M at FY25), Top-3 U.S. wholesaler concentration (McKesson 32%, Cencora 24%, Cardinal Health 14% of FY25 revenue; 82% of gross trade AR), and blockbuster breadth (12 products >$1B = 65% of FY25 Biopharma revenue); (6) Standalone summarized financials of ViiV Healthcare Limited (11.7% equity-method HIV JV: $9,517M revenue / $2,487M net income in FY25), collaborative profit-sharing flows, and M&A contingent consideration; (7) Enterprise Cost Realignment ($4,900M cumulative costs through Q2 2026) & Manufacturing Optimization ($1,100M cumulative costs), ASU 2023-07 Biopharma segment expense lines, and Non-GAAP Adjusted Income ($4,458M / $0.78 EPS in Q2 2026); (8–9) 36 global manufacturing sites, inventory stages, intangibles & 5-year amortization schedule, pension obligations/assets, unrecognized tax benefits, 75,000 global employees, CEO Pay Ratio (277:1 in FY25), Form 11-K U.S. ($24.20B net assets) & Puerto Rico Savings Plans, FDA inspections/recalls, safety (0.28 TIR), and Scope 1–3 GHG/water/waste.
Không hiện vì thiếu các kỳ gần đây (33)
- Core Operational KPIs — R&D Pipeline, Patient Reach, Pricing, Guidance & Backlog › Consolidated Operational Revenue Growth Excluding Comirnaty & Paxlovid YoY (%) › Operational growth of recently launched & acquired products YoY (%)
- Primary Care — Brand Revenues (Eliquis, Prevnar, Nurtec ODT, Vaccines & COVID-19) › Nurtec ODT / Vydura (rimegepant — migraine, acquired via Biohaven) — Worldwide revenues ($M) › Nurtec ODT / Vydura (rimegepant — migraine, acquired via Biohaven) — International revenues ($M) › Nurtec ODT / Vydura (rimegepant — migraine, acquired via Biohaven) — International reported YoY (%)
- Primary Care — Brand Revenues (Eliquis, Prevnar, Nurtec ODT, Vaccines & COVID-19) › Nurtec ODT / Vydura (rimegepant — migraine, acquired via Biohaven) — Worldwide revenues ($M) › Nurtec ODT / Vydura (rimegepant — migraine, acquired via Biohaven) — International revenues ($M) › Nurtec ODT / Vydura (rimegepant — migraine, acquired via Biohaven) — International operational (constant-currency) YoY (%)
- Primary Care — Brand Revenues (Eliquis, Prevnar, Nurtec ODT, Vaccines & COVID-19) › Abrysvo (bivalent RSV vaccine — maternal & older adults) — Worldwide revenues ($M) › Abrysvo (bivalent RSV vaccine — maternal & older adults) — International revenues ($M) › Abrysvo (bivalent RSV vaccine — maternal & older adults) — International reported YoY (%)
- Primary Care — Brand Revenues (Eliquis, Prevnar, Nurtec ODT, Vaccines & COVID-19) › Abrysvo (bivalent RSV vaccine — maternal & older adults) — Worldwide revenues ($M) › Abrysvo (bivalent RSV vaccine — maternal & older adults) — International revenues ($M) › Abrysvo (bivalent RSV vaccine — maternal & older adults) — International operational (constant-currency) YoY (%)
- Primary Care — Brand Revenues (Eliquis, Prevnar, Nurtec ODT, Vaccines & COVID-19) › Primary Care Portfolio (Q1 2026 realigned basis) — Worldwide ($M) › Primary Care Portfolio (Q1 2026 realigned basis) — U.S. ($M)
- Primary Care — Brand Revenues (Eliquis, Prevnar, Nurtec ODT, Vaccines & COVID-19) › Primary Care Portfolio (Q1 2026 realigned basis) — Worldwide ($M) › Primary Care Portfolio (Q1 2026 realigned basis) — International ($M)
- Primary Care — Brand Revenues (Eliquis, Prevnar, Nurtec ODT, Vaccines & COVID-19) › Primary Care Portfolio (Q1 2026 realigned basis) — Worldwide ($M)
- Oncology — Brand Revenues (Ibrance, Padcev, Xtandi, Seagen ADC Franchise & Targeted Therapies) › Padcev (enfortumab vedotin ADC — urothelial cancer, via Seagen) — Worldwide revenues ($M) › Padcev (enfortumab vedotin ADC — urothelial cancer, via Seagen) — International revenues ($M) › Padcev (enfortumab vedotin ADC — urothelial cancer, via Seagen) — International reported YoY (%)
- Oncology — Brand Revenues (Ibrance, Padcev, Xtandi, Seagen ADC Franchise & Targeted Therapies) › Padcev (enfortumab vedotin ADC — urothelial cancer, via Seagen) — Worldwide revenues ($M) › Padcev (enfortumab vedotin ADC — urothelial cancer, via Seagen) — International revenues ($M) › Padcev (enfortumab vedotin ADC — urothelial cancer, via Seagen) — International operational (constant-currency) YoY (%)
- Oncology — Brand Revenues (Ibrance, Padcev, Xtandi, Seagen ADC Franchise & Targeted Therapies) › Orgovyx (relugolix — prostate cancer, Sumitomo collaboration) — Worldwide revenues ($M) › Orgovyx (relugolix — prostate cancer, Sumitomo collaboration) — U.S. revenues ($M) › Orgovyx (relugolix — prostate cancer, Sumitomo collaboration) — U.S. reported YoY (%)
- Oncology — Brand Revenues (Ibrance, Padcev, Xtandi, Seagen ADC Franchise & Targeted Therapies) › Orgovyx (relugolix — prostate cancer, Sumitomo collaboration) — Worldwide revenues ($M) › Orgovyx (relugolix — prostate cancer, Sumitomo collaboration) — Worldwide reported YoY (%)
- Oncology — Brand Revenues (Ibrance, Padcev, Xtandi, Seagen ADC Franchise & Targeted Therapies) › Orgovyx (relugolix — prostate cancer, Sumitomo collaboration) — Worldwide revenues ($M) › Orgovyx (relugolix — prostate cancer, Sumitomo collaboration) — Worldwide operational (constant-currency) YoY (%)
- Oncology — Brand Revenues (Ibrance, Padcev, Xtandi, Seagen ADC Franchise & Targeted Therapies) › Tivdak (tisotumab vedotin ADC — cervical cancer, via Seagen) — Worldwide revenues ($M) › Tivdak (tisotumab vedotin ADC — cervical cancer, via Seagen) — U.S. revenues ($M) › Tivdak (tisotumab vedotin ADC — cervical cancer, via Seagen) — U.S. reported YoY (%)
- Oncology — Brand Revenues (Ibrance, Padcev, Xtandi, Seagen ADC Franchise & Targeted Therapies) › Tivdak (tisotumab vedotin ADC — cervical cancer, via Seagen) — Worldwide revenues ($M) › Tivdak (tisotumab vedotin ADC — cervical cancer, via Seagen) — International revenues ($M) › Tivdak (tisotumab vedotin ADC — cervical cancer, via Seagen) — International reported YoY (%)
- Oncology — Brand Revenues (Ibrance, Padcev, Xtandi, Seagen ADC Franchise & Targeted Therapies) › Tivdak (tisotumab vedotin ADC — cervical cancer, via Seagen) — Worldwide revenues ($M) › Tivdak (tisotumab vedotin ADC — cervical cancer, via Seagen) — International revenues ($M) › Tivdak (tisotumab vedotin ADC — cervical cancer, via Seagen) — International operational (constant-currency) YoY (%)
- Oncology — Brand Revenues (Ibrance, Padcev, Xtandi, Seagen ADC Franchise & Targeted Therapies) › All Other Oncology — Worldwide revenues ($M) › All Other Oncology — Worldwide reported YoY (%)
- Oncology — Brand Revenues (Ibrance, Padcev, Xtandi, Seagen ADC Franchise & Targeted Therapies) › Oncology Portfolio (Q1 2026 realigned basis, excl. Oncology Biosimilars) — Worldwide ($M) › Oncology Portfolio (Q1 2026 realigned basis) — U.S. ($M)
- Oncology — Brand Revenues (Ibrance, Padcev, Xtandi, Seagen ADC Franchise & Targeted Therapies) › Oncology Portfolio (Q1 2026 realigned basis, excl. Oncology Biosimilars) — Worldwide ($M) › Oncology Portfolio (Q1 2026 realigned basis) — International ($M)
- Oncology — Brand Revenues (Ibrance, Padcev, Xtandi, Seagen ADC Franchise & Targeted Therapies) › Oncology Portfolio (Q1 2026 realigned basis, excl. Oncology Biosimilars) — Worldwide ($M)
- Specialty Care, Global Hospital & Biosimilars, Alliance/Royalty & CDMO › Sulperazon (cefoperazone/sulbactam — hospital anti-infective) — Worldwide revenues ($M) › Sulperazon (cefoperazone/sulbactam — hospital anti-infective) — U.S. revenues ($M) › Sulperazon (cefoperazone/sulbactam — hospital anti-infective) — U.S. reported YoY (%)
- Specialty Care, Global Hospital & Biosimilars, Alliance/Royalty & CDMO › Sulperazon (cefoperazone/sulbactam — hospital anti-infective) — Worldwide revenues ($M) › Sulperazon (cefoperazone/sulbactam — hospital anti-infective) — U.S. revenues ($M)
- Specialty Care, Global Hospital & Biosimilars, Alliance/Royalty & CDMO › Zavicefta (ceftazidime/avibactam — Gram-negative anti-infective) — Worldwide revenues ($M) › Zavicefta (ceftazidime/avibactam — Gram-negative anti-infective) — U.S. revenues ($M) › Zavicefta (ceftazidime/avibactam — Gram-negative anti-infective) — U.S. reported YoY (%)
- Specialty Care, Global Hospital & Biosimilars, Alliance/Royalty & CDMO › Zavicefta (ceftazidime/avibactam — Gram-negative anti-infective) — Worldwide revenues ($M) › Zavicefta (ceftazidime/avibactam — Gram-negative anti-infective) — U.S. revenues ($M)
- Specialty Care, Global Hospital & Biosimilars, Alliance/Royalty & CDMO › Enbrel (etanercept — international outside U.S./Canada) — Worldwide revenues ($M) › Enbrel (etanercept — international outside U.S./Canada) — U.S. revenues ($M) › Enbrel (etanercept — international outside U.S./Canada) — U.S. reported YoY (%)
- Specialty Care, Global Hospital & Biosimilars, Alliance/Royalty & CDMO › Enbrel (etanercept — international outside U.S./Canada) — Worldwide revenues ($M) › Enbrel (etanercept — international outside U.S./Canada) — U.S. revenues ($M)
- Specialty Care, Global Hospital & Biosimilars, Alliance/Royalty & CDMO › Zithromax (azithromycin) — Worldwide revenues ($M) › Zithromax (azithromycin) — U.S. revenues ($M)
- Specialty Care, Global Hospital & Biosimilars, Alliance/Royalty & CDMO › Specialty Care Portfolio (Q1 2026 realigned basis) — Worldwide ($M)
- Specialty Care, Global Hospital & Biosimilars, Alliance/Royalty & CDMO › Global Hospital & Biosimilars Portfolio (created Q1 2026) — Worldwide ($M)
- Joint Venture (ViiV Healthcare), Collaborative Profit-Sharing & Contingent Consideration › Acquisition Contingent Consideration Liabilities — Current fair value ($M) › Fair value remeasurement of contingent consideration in P&L ($M)
- Workforce, Form 11-K Savings Plans, Governance, FDA Quality & Environmental Impact › Supply Chain 3TG Conflict Minerals (Form SD) — Known smelters & refiners › Form SD — RMAP-conformant 3TG smelters & refiners
- Workforce, Form 11-K Savings Plans, Governance, FDA Quality & Environmental Impact › Supply Chain 3TG Conflict Minerals (Form SD) — Known smelters & refiners
- Consolidated Segment & Financial Statement Context (Database) › DB Segment — Biopharma Segment Revenues ($M) › DB Revenue Type — Alliance Revenues ($M)
Dữ liệu cập nhật 2026-11-02.
Mỗi KPI một trang riêng
Đầy đủ lịch sử, biểu đồ, nguồn và cách trích dẫn cho từng chỉ số
Core Operational KPIs — R&D Pipeline, Patient Reach, Pricing, Guidance & Backlog
- Total R&D Pipeline Programs (Phase 1 through Registration)5 kỳ
- Patients Treated Worldwide — Total including COVID-19 products (millions) (M)3 kỳ
- U.S. Portfolio Average Net Price Change YoY — Total portfolio (%) (%)3 kỳ
- Consolidated Operational Revenue Growth Excluding Comirnaty & Paxlovid YoY (%) (%)16 kỳ
- Full-Year Revenue Guidance — Lower end ($M) ($M)29 kỳ
- Deferred Revenue / Contract Liabilities — Government COVID-19 supply agreements ($M) ($M)14 kỳ
Primary Care — Brand Revenues (Eliquis, Prevnar, Nurtec ODT, Vaccines & COVID-19)
- Eliquis (apixaban — BMS alliance & direct sales) — Worldwide revenues ($M) ($M)39 kỳ
- Prevnar Family (Prevnar 20 / Apexxnar & Prevnar 13 pneumococcal vaccines) — Worldwide revenues ($M) ($M)39 kỳ
- Comirnaty (COVID-19 mRNA vaccine — BioNTech collaboration) — Worldwide revenues ($M) ($M)26 kỳ
- Paxlovid (nirmatrelvir/ritonavir oral COVID-19 treatment) — Worldwide revenues ($M) ($M)22 kỳ
- Nurtec ODT / Vydura (rimegepant — migraine, acquired via Biohaven) — Worldwide revenues ($M) ($M)18 kỳ
- Abrysvo (bivalent RSV vaccine — maternal & older adults) — Worldwide revenues ($M) ($M)16 kỳ
- FSME-IMMUN / TicoVac (tick-borne encephalitis vaccine) — Worldwide revenues ($M) ($M)33 kỳ
- All Other Primary Care — Worldwide revenues ($M) ($M)20 kỳ
- Primary Care Portfolio Total [legacy pre-Q1 2026 realignment, through Q4 2025] ($M) ($M)18 kỳ
Oncology — Brand Revenues (Ibrance, Padcev, Xtandi, Seagen ADC Franchise & Targeted Therapies)
- Ibrance (palbociclib — HR+/HER2- metastatic breast cancer) — Worldwide revenues ($M) ($M)39 kỳ
- Xtandi (enzalutamide — alliance & royalty revenue with Astellas) — Worldwide revenues ($M) ($M)39 kỳ
- Padcev (enfortumab vedotin ADC — urothelial cancer, via Seagen) — Worldwide revenues ($M) ($M)14 kỳ
- Lorbrena / Lorviqua (lorlatinib — ALK+ NSCLC) — Worldwide revenues ($M) ($M)28 kỳ
- Adcetris (brentuximab vedotin ADC — lymphoma, via Seagen) — Worldwide revenues ($M) ($M)14 kỳ
- Inlyta (axitinib — renal cell carcinoma) — Worldwide revenues ($M) ($M)39 kỳ
- Braftovi + Mektovi (encorafenib / binimetinib — BRAF+ melanoma/CRC/NSCLC) — Worldwide revenues ($M) ($M)14 kỳ
- Bosulif (bosutinib — CML) — Worldwide revenues ($M) ($M)39 kỳ
- Tukysa (tucatinib — HER2+ breast/colorectal cancer, via Seagen) — Worldwide revenues ($M) ($M)14 kỳ
- Orgovyx (relugolix — prostate cancer, Sumitomo collaboration) — Worldwide revenues ($M) ($M)8 kỳ
- Elrexfio (elranatamab — BCMA bispecific for multiple myeloma) — Worldwide revenues ($M) ($M)11 kỳ
- Talzenna (talazoparib — PARP inhibitor) — Worldwide revenues ($M) ($M)14 kỳ
- Tivdak (tisotumab vedotin ADC — cervical cancer, via Seagen) — Worldwide revenues ($M) ($M)14 kỳ
- All Other Oncology — Worldwide revenues ($M) ($M)39 kỳ
- Oncology Portfolio Total [legacy incl. Oncology Biosimilars, through Q4 2025] ($M) ($M)37 kỳ
Specialty Care, Global Hospital & Biosimilars, Alliance/Royalty & CDMO
- Vyndaqel Family (Vyndaqel / Vyndamax / Vynmac — ATTR-CM) — Worldwide revenues ($M) ($M)33 kỳ
- Xeljanz (tofacitinib — rheumatoid arthritis / ulcerative colitis) — Worldwide revenues ($M) ($M)39 kỳ
- Oncology Biosimilars Portfolio (Ruxience, Zirabev, Trazimera, Nivestym, Nyvepria) — Worldwide revenues ($M) ($M)14 kỳ
- Sulperazon (cefoperazone/sulbactam — hospital anti-infective) — Worldwide revenues ($M) ($M)39 kỳ
- Octagam / Panzyga (immunoglobulin portfolio) — Worldwide revenues ($M) ($M)21 kỳ
- Inflectra / Remsima (infliximab biosimilar) — Worldwide revenues ($M) ($M)39 kỳ
- Zavicefta (ceftazidime/avibactam — Gram-negative anti-infective) — Worldwide revenues ($M) ($M)27 kỳ
- Enbrel (etanercept — international outside U.S./Canada) — Worldwide revenues ($M) ($M)39 kỳ
- Genotropin (somatropin — growth hormone) — Worldwide revenues ($M) ($M)39 kỳ
- Zithromax (azithromycin) — Worldwide revenues ($M) ($M)39 kỳ
- Cibinqo (abrocitinib — atopic dermatitis) — Worldwide revenues ($M) ($M)17 kỳ
- Cresemba (isavuconazole — invasive fungal infections, annual 10-K/8-K) ($M) ($M)5 kỳ
- All Other Specialty Care — Worldwide revenues ($M) ($M)20 kỳ
- Total Biopharma Alliance Revenues (cross-portfolio summary) — Worldwide revenues ($M) ($M)39 kỳ
- Total Biopharma Royalty Revenues (cross-portfolio summary) — Worldwide revenues ($M) ($M)14 kỳ
- Pfizer CentreOne (Contract Development & Manufacturing Organization — CDMO) — Worldwide revenues ($M) ($M)39 kỳ
- Pfizer Ignite (end-to-end biotech R&D services) [legacy through Q4 2025] ($M) ($M)16 kỳ
- Specialty Care Portfolio Total [legacy pre-Q1 2026 realignment, through Q4 2025] ($M) ($M)18 kỳ
- U.S. Commercial Division Revenues [legacy 2024–2025 structure] ($M) ($M)12 kỳ
- Historical / Mature / Divested Brands [legacy disclosures] — Vyndaqel/Hospital/Upjohn history ($M) ($M)11 kỳ
Gross-to-Net (GTN) Rebates, Wholesaler Concentration & Blockbuster Breadth
Joint Venture (ViiV Healthcare), Collaborative Profit-Sharing & Contingent Consideration
Cost Realignment, Mfg Optimization, Segment P&L (ASU 2023-07) & Non-GAAP Earnings
Manufacturing Network, Inventories, Intangibles/IPR&D, Leases, Pension & Taxes
- Global Manufacturing Network — Owned & operated manufacturing sites10 kỳ
- Inventories — Work-in-process ($M) ($M)46 kỳ
- Finite-Lived Intangible Assets — Net carrying amount ($M) ($M)46 kỳ
- Property, Plant & Equipment — Gross carrying value ($M) ($M)11 kỳ
- U.S. Defined Benefit Pension Plans — Projected benefit obligation (PBO) ($M) ($M)11 kỳ
- Unrecognized Tax Benefits (UTB) — Ending gross balance ($M) ($M)11 kỳ
Workforce, Form 11-K Savings Plans, Governance, FDA Quality & Environmental Impact
- Global Workforce — Total employees worldwide11 kỳ
- CEO Pay Ratio (CEO total compensation ÷ median global employee compensation, x) (×)7 kỳ
- Pfizer U.S. Savings Plan (Form 11-K) — Net assets available for benefits ($M) ($M)9 kỳ
- Regulatory Quality — FDA GxP inspections across Pfizer sites3 kỳ
- Climate — Scope 1 & 2 Market-Based GHG Emissions (million metric tons CO2e) (M)5 kỳ
U.S. Pharmaceutical & Healthcare Industry Benchmarks (Monthly / Quarterly — FRED)
- U.S. Producer Price Index — Pharmaceutical Preparation Mfg (Index, Dec 1981=100)129 kỳ
- U.S. Consumer Price Index — Medical Care Commodities (Index, 1982–84=100, SA)128 kỳ
- U.S. Industrial Production — Pharmaceutical & Medicine Mfg (Index, 2017=100, SA)129 kỳ
- U.S. Retail Sales — Pharmacies & Drug Stores, Seasonally Adjusted ($M) ($M)128 kỳ
- U.S. Retail Sales — Pharmacies & Drug Stores, Not Seasonally Adjusted ($M) ($M)128 kỳ
- U.S. All Employees — Health Care Sector (thousands, SA)129 kỳ
- U.S. Real Personal Consumption Expenditures — Pharmaceutical & Medical Products ($B SAAR) ($M)42 kỳ
Consolidated Segment & Financial Statement Context (Database)
Tài liệu nguồn mới nhất
Các tài liệu được trích nhiều nhất cho số liệu mới nhất của Pfizer
- Form 8-K (Earnings / Guidance Release) (pfe-12312025xex99.htm, filed 2026-02-03) ↗
- Form 8-K (Earnings / Guidance Release) (pfe-6282026xex99.htm, filed 2026-08-04) ↗
- Form 10-Q (filed 2026-08-04) ↗
- Form 10-K (filed 2026-02-26) ↗
- Pfizer Official Report — Pfizer 2025 Impact Report 02JUN2026 ↗
- Form 10-K (pfe-20251231.htm, filed 2026-02-26) ↗
- Pfizer Official Report — Q2 2026 Pipeline Update Final ↗
- Pfizer Official Report — Q4 2025 Pipeline Update vFinal3 ↗
- Form 10-Q (filed 2020-11-05) ↗
- Form 10-K (filed 2020-02-27) ↗
- DEF 14A (Proxy Statement) (pfe-20260312.htm, filed 2026-03-12) ↗
- Form 11-K (Pfizer Savings Plan) (pfe-20260615.htm, filed 2026-06-16) ↗
See a number that looks wrong?